A Phase I, Open-label, Randomized, Single-dose, 2-panel, Crossover Trial in Healthy Subjects to Assess the Relative Bioavailability of TMC435 HPMC Capsule Compared to the TMC435 Gelatin Capsule and to Assess the Effect of Different Meal Types on the Bioavailability of Both Formulations
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 主要终点
- Absorption of TMC435 following administration of the HPMC capsule and of the gelatin capsule
研究概览
简要总结
The purpose of this study is to compare absorption of TMC435 formulated as 2 different types of capsules. After that, the absorption of one chosen TMC435 capsule will be compared when taken under fasting conditions or together with a standard or a high-fat meal. This will be done in healthy volunteers.
详细描述
This is an open-label, randomized, single-dose, crossover trial in healthy volunteers. Crossover means that participants may receive different interventions sequentially during the trial. Randomized means that you will be assigned to a treatment sequence by chance, like flipping a coin. Open-label means that you and your physician will know what treatment you will receive. The study will consist of 3 phases: a screening phase, a treatment phase and a follow-up phase. Total study duration for an individual participant will be up to 6 or 7 weeks. Once found eligible after the screening phase, participants will take part in one of the two parts of the treatment phase. In the first part, a group of 24 participants will receive two treatment sessions, A and B. The order in which the treatments are given will be determined by chance. Treatment A is a single dose of TMC345 as one formulation (1 capsule). Treatment B is a single dose of TMC435 as another formulation (1 other type of capsule). Both treatments will be taken without food. In between the 2 sessions, there will be at least 7 days. In the second part, another group of 24 participants will receive 3 treatment sessions, C, D, and E. The order in which these treatments are given will be determined by chance. All 3 treatments will consist of a single dose of TMC435 as one of the 2 formulations given in the first part. In Treatment C this will be given without food, in Treatment D with a standardized breakfast and in Treatment E with a high-fat breakfast. In between the sessions, there will be at least 7 days. For all treatment sessions, participants will enter the study center the day before dosing and will remain there until the evening of the day after. The 3 following mornings, participants will come back to the study center. Five to 7 days after dosing, participants will have a last follow-up visit at the study center (follow-up phase). During the study, safety will be monitored, and during the treatment phase, at specified timepoints, blood samples will be taken for pharmacokinetic evalutions (effect of the body on the drug). In every treatment session, a single oral 150 mg TMC435 capsule will be given. One formulation will be a gelatin capsule. The other formulation will be a hydroxypropylmethylcellulose (HPMC) capsule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Non-smokers for at least 3 months prior to screening
- •Have a body mass index of 18.0 to 30.0 kg per square meter
- •Be healthy on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening
排除标准
- •Use of disallowed therapies, including over-the-counter products and dietary supplements
- •Having previously participated in a multiple-dose trial or more than 3 single-dose trials with TMC435
- •Received an investigational drug or used an investigational medical device within 90 days before the planned start of treatment
- •History or evidence of current use of alcohol, barbiturate, amphetamine, recreational, or narcotic drug use
研究组 & 干预措施
001
TMC435 gelatin capsule Single intake of one 150-mg capsule without food
干预措施: TMC435 gelatin capsule (Drug)
002
TMC435 HPMC capsule Single intake of one 150-mg capsule without food
干预措施: TMC435 HPMC capsule (Drug)
003
TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
干预措施: TMC435 HPMC or gelatin capsule (Drug)
004
TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
干预措施: TMC435 HPMC or gelatin capsule (Drug)
005
TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
干预措施: TMC435 HPMC or gelatin capsule (Drug)
结局指标
主要结局
Absorption of TMC435 following administration of the HPMC capsule and of the gelatin capsule
时间窗: Over 72 hours for every treatment session
Absorption of TMC435 following administration of the HPMC or gelatin capsule in the fed (following different meal types) and fasted state
时间窗: Over 72 hours for every treatment session
次要结局
- Number of participants with adverse events and the severity of adverse events(During maximum 7 weeks)
- Percentage of abnormal values for laboratory parameters(Up to maximum 7 weeks)
- Observed values and changes from baseline of cardiovascular variables(Up to maximum 7 weeks)
- Evaluation of pulse and blood pressure values, based on changes from baseline and the percentage of participants with values beyond clinically important limits(Up to maximum 7 weeks)
- Physical examination findings and changes from baseline.(Up to maximum 7 weeks)